GHK-Cu Telehealth

GHK-Cu Dosage in Research: Topical, Injectable, and Intranasal Protocols

Research-Context Dosing: What the Literature Reports

GHK-Cu is a research peptide — it has no FDA-approved therapeutic indication for injectable or systemic use. The dosing information below describes what was administered in published research protocols, organized by study type and model. This is not a dosing guide; it is a summary of what has been studied.

Understanding GHK-Cu dosage parameters requires distinguishing topical use (where controlled human trial data exist) from injectable use (where the literature is entirely preclinical).

GHK-Cu Dosage Parameters in Research Literature

Topical (cosmetic and clinical formulations)

Concentrations between 0.1% and 5% GHK-Cu have been used in cosmetic serum and cream formulations studied in placebo-controlled trials. The 12-week photoaging trial [4] and the 8-week nano-lipid carrier study [6] used topical formulations without specifying concentration in the published abstracts; the 6-month hair growth RCT used a complex formulation at 100 mg/mL and 50 mg/mL [12].

A 2025 review characterized topical delivery challenges directly: GHK-Cu's clogP of -2.24 restricts passive stratum corneum penetration. Palmitoylated GHK-Cu (Pal-GHK) achieves 4.61% penetration vs. native GHK-Cu at much lower rates [24]. Liposomal encapsulation, ionic liquid microemulsions, and microneedle pretreatment are under active investigation as enhancement strategies [8][13][24].

An ex vivo human skin diffusion study established a permeability coefficient of 2.43±0.51×10⁻⁴ cm/h for GHK-Cu through dermatomed skin, with 97±6.6 μg/cm² retained as a dermal depot over 48 hours [20]. This indicates that topically applied GHK-Cu does penetrate to the dermis and form a local reservoir — supporting the mechanism by which topical formulations reach dermal fibroblasts.

Injectable (rodent preclinical)

Published rodent injectable doses vary by model:

  • Emphysema (COPD mouse model): 0.2, 2, and 20 μg/g/day intraperitoneal on alternate days [10]
  • Pulmonary fibrosis (bleomycin model): 2.6, 26, and 260 μg/mL/day intraperitoneal from day 4–21 [11]
  • Silicosis model: 2 and 20 mg/kg intraperitoneal [18]

Intranasal (rodent cognitive models)

  • Aging mice (20 months old): 15 mg/kg/day intranasal for 8 weeks [14]
  • 5xFAD Alzheimer's model: 15 mg/kg three times weekly for 3 months [15]

In vitro effective range

Collagen and glycosaminoglycan synthesis stimulation in human fibroblast cultures: 10⁻¹² to 10⁻⁹ M (with maximum activity at 10⁻⁹ M) [1]. Keratinocyte proliferation studies used 1–10 nM concentrations [5].

GHK-Cu Pharmacokinetics and Half-Life

No rigorous human pharmacokinetic study has been published for GHK-Cu. Half-life, peak plasma concentration (Cmax), area under the curve, bioavailability, or tissue distribution after subcutaneous or intranasal administration in humans are not available in the published literature.

What is known:

  • GHK-Cu is a small tripeptide (340.4 Da). Small peptides are subject to peptidase degradation in plasma.
  • Subcutaneous or intranasal administration would bypass first-pass hepatic metabolism.
  • Topical application creates a dermal depot: 97 μg/cm² retained over 48 hours in an ex vivo diffusion study [20], suggesting prolonged local availability at the application site.
  • Plasma GHK levels in healthy adults are endogenous and measurable (approximately 200 ng/mL at age 20, 80 ng/mL by age 60 [3]); exogenous GHK-Cu administration would add to this baseline.

Pickart estimated a human therapeutic systemic dose in the range of 100–200 mg based on rodent effective-dose extrapolation, but this estimate has not been validated in published human trials.

For researchers investigating GHK-Cu, the pharmacokinetic gap is one of the most significant open questions in the literature.

Administration Routes in GHK-Cu Research

Published research has used the following administration routes:

  1. Topical (serums, creams, nano-lipid carriers, liposomes, ionic liquid microemulsions, wound dressings) — the most studied route; multiple human controlled trials confirm skin delivery and efficacy endpoints [4][6][8][13][20][24]
  2. Intraperitoneal injection — standard rodent route; used in COPD, fibrosis, silicosis, and acute lung injury models [10][11][18]
  3. Intranasal — used specifically in aging and Alzheimer's mouse models to target central nervous system effects without peripheral injection [14][15]
  4. Wound dressing matrix — collagen dressings loaded with GHK-Cu applied directly to wound surfaces in diabetic and ischemic rodent models [7]

Intraperitoneal injection is a rodent-specific administration route that does not correspond to common human parenteral routes (subcutaneous, intramuscular, intravenous). Translating rodent IP doses to human dosing requires species-scale adjustment and pharmacokinetic studies that have not been published for GHK-Cu.

For injectable preparations used in some functional medicine or research contexts: these are not FDA-approved therapeutic formulations, and no published clinical trial data characterize their efficacy, dosing, or safety in humans.

Formulation and Stability Considerations

GHK-Cu stability is pH-sensitive. The copper-peptide complex is more stable at physiological pH (7.4) than at acidic pH. Common cosmetic acidic actives — AHAs (glycolic acid, lactic acid), BHAs (salicylic acid), and high-concentration vitamin C serums — can destabilize GHK-Cu or compete for copper binding [24].

Separate application timing (e.g., morning vs. evening) is the standard recommendation in topical formulation protocols when GHK-Cu is used alongside acidic actives.

Advanced delivery systems under investigation:

  • Liposomal encapsulation: improves stability and skin penetration; studied in wound healing models [8]
  • Nano-lipid carriers (NLC): 8-week human trial achieved 31.6% wrinkle reduction [6]
  • Ionic liquid microemulsions: 2% GHK-Cu CaT-ME formulation drove follicles into anagen in 6 days in mice (vs. 9 days for topical minoxidil) [13]
  • Palmitoylation (Pal-GHK-Cu): increases lipophilicity; 4.61% stratum corneum penetration vs. much lower rates for native GHK-Cu [24]
  • Cell-penetrating peptide (CPP) conjugates: early-stage delivery enhancement strategy identified in 2025 review [24]
  • Microneedle pretreatment: bypasses stratum corneum barrier; identified in 2025 review as an evidence-based enhancement approach [24]

The formulation question is currently one of the most active areas of GHK-Cu applied research.